Clinical Trial Highlights

• JAK2-STAT3 Signaling Implicated in the Regulation of Hepatic TPO Production
• AALL0434 Treatment Therapy Has Excellent Outcomes in Children With T-ALL
• Clonal Mapping of Hematopoiesis In Vivo Provides Direction for New Clinical Protocols
• Activity of Lenalidomide in MDS Tied to Degradation of CSNK1A1
• Th17-Prone CD146⁺CCR5⁺ T-Cell Population Is an Early Marker of Intestinal GVHD
• Sorafenib as Effective Treatment for Newly Diagnosed AML in Younger Patients
• FXI-ASO May Represent a New Class of Antithrombotic Agents
• Benefit of Extended Anticoagulation After Unprovoked PE Lost After Treatment Discontinuation
• Tinzaparin Reduces the Risk of Recurrent Thromboembolic Events in Patients With Cancer
• AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question
• Idarucizumab Reverses Dabigatran in Elderly or Renally Impaired
• Vosaroxin in Combination With Cytarabine Provides a New Salvage Option for AML
• FCR Superior in Treatment of Advanced CLL
• CKT Implicated in Worse Outcomes With Ibrutinib Therapy of CLL
• MRD and Clinical Response Predictors of PFS in CLL
• Noninvasive Detection of Genomic Imbalances in HL Is Promising
• Dasatinib Outcomes Maintained Over 5 Years
• Reduced-Dose Conditioning Comparable to Standard Dose Prior to ASCT in MDS
• 4F-PCC Reverses Apixaban Anticoagulation in Healthy Volunteers
• PCC Reverses Dabigatran-Associated Bleeding in Polytrauma Model